Integrating biological agents into systemic therapy of breast cancer: Trastuzumab, lapatinib, bevacizumab

Journal of B.U.ON.

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Eniu, Alexandru ^a  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

Biologic agents; Breast cancer; Systemic therapy; Targeted therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BRAIN METASTASIS; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EARLY CANCER; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PROTEINURIA; RISK REDUCTION; SIDE EFFECT;

EID: 36749072614     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
3. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-1056.
4. Hynes NE, Stem DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
5. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112.
6. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 27 (5 Suppl 9): 13-19.
7. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61 (Suppl 2): 14-21.
8. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
9. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
10. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418-423.
11. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24: 3032-3038.
12. Wolff AC, Hammond ME, Schwartz fN et al. American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
13. Harris AK, Washington CB, Lieberman G et al. A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. J Clin Oncol 2002; 21: 123 (abstr 488).
14. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
15. Burstein HJ, Harris LN, Marcorn PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-2895.
16. Schaller G, Bangemann N, Weber J et al. Efficacy and safety of trastuzumab plus capecitabine in a German multicenter phase II study of pre-treated metastatic breast cancer. J Clin Oncol 2005; 23: 57s (abstr).
17. O'Shaughnessy JA, Vukelja S, Marsland T et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004; 5: 142-147.
18. Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007 (published on line Jul 5, 2007).
19. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-2792.
20. Pegram JF, Pienkowski T, Valero V et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25(18S): 1008 (abstr).
21. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551.
22. Seidman AD, Norton L. Paclitaxel, Carboplatin, and Trastuzumab in HER2-positive Metastatic Breast Cancer. Curr Oncol Rep 2005; 7: 9-11.
23. Mackey JR KB CM, Clemens M et al. Trastuzumab prolongs progression free survival in hormone-dependent and HER2+ metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl1): 3a (abstr).
24. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
25. Perez EA, Suman VJ, Jeong J et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25 (18S): 512 (abstr).
26. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
27. Slamon D, Eiermann W, Robert N et al. BCIRG 006: Second interim analysis of phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trustuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Breast Cancer Res Treat 2006; Presented at the San Antonio Breast Cancer Symposium, San Antonio, Tx, December 13-16, 2006.
28. Joensuu H, Kellokampu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
29. Chien KR. Herceptin and the heart: a molecular modifier of cardiac failure. N Engl J Med 2006; 354: 789-790.
30. Rastogi P, Jeong J, Geyer CE et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC) ← paclitaxel (T) vs. AT ← with trastuzumab (H). J Clin Oncol 2007; 25: LBA 513, 18s (abstr).
31. Baselga J, Cameron D, Miles D et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER.2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol 2007; 25 (18S): 1004 (abstr).
32. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER.2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
33. Lin NU, Dieras V, Paul D et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 2007; 25 (18s): 1012 (abstr).
34. Perez EA, Byme JA, Rappold E et al. Cardiac Safety Experience in 3558 Patients Treated With Lapatinib. Ann Oncol 2006; 17 (Suppl 10): 345 (abstr).
35. Mi1ler KD WM, Gralow J, Dickler Metal. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2 100). Breast Cancer Res Treat 2005; 94 (S6): 3 (abstr).